P18.10 Impact of glioblastoma multiforme (GBM) on patients’ quality of life (QoL)

Abstract

OBJECTIVE: To assess the QoL reported by GBM patients and their caregivers METHODOLOGY: Real-world data were collected through a cross-sectional survey administered to physicians, patients, and caregivers in France, Germany, and the UK between May and July 2016. Physicians confirmed diagnosis and assessed patients as having progressed, being stable, or responding to treatment. Patient-reported outcomes (PROs) were measured using the 3-level EQ-5D as well as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and brain cancer-specific module (QLQ-BN20). For patients who could not complete the EQ-5D, proxy assessments were obtained from caregivers. Summary statistics were reported and differences were assessed using pairwise t tests. RESULT(S): A total of 313 GBM patients completed the PRO measures, while 203 caregivers provided a proxy EQ-5D assessment. Patient QoL was poor as indicated by a mean (SD) EQ-5D index score of 0.51 (0.38). Significant differences were observed among patient groups defined according to progression. Those whose disease had progressed had a mean (SD) index score of 0.26 (0.38) compared with 0.53 (0.37 p<0.001) for those with stable disease, and with 0.61 (0.34 p<0.001) for those with treatment-responsive disease. Proxy EQ-5D results from caregivers were qualitatively similar-progressed vs. stable (0.38 (0.37) vs. 0.43 (0.37) (p=0.178)), and progressed vs. treatment-responsive (0.38 (0.37) vs. 0.47 (0.37) (p=0.178)). Patient health status, indicated by the EORTC QLQ-C30 global health scale, was poor with a mean (SD) score of 44.0 (20.9). Patients with progressed disease reported a health status mean (SD) score of 35.3 (19.5), worse than stable patients 44.9 (21.6) (p<0.001) and worse than treatment-responsive patients 47.6 (22.6) (p<0.001). Similar differences were observed with regard to physical and cognitive functioning. For physical function mean (SD) scores for progressed were 47.8 (22.6) compared to stable 58.6 (24.8) (p<0.001) and to treatment responsive 65.4 (23.4) (p<0.001). With cognitive function mean (SD) scores were progressed 43.6 (28.2) compared to stable 54.7 (24.8) (p<0.001) and again to treatment responsive 56.2 (25.1) (p<0.001). Symptom burden, as measured using the EORTC QLQ-BN20, was also pronounced. Mean (SD) scores for scales measuring communication deficit, motor dysfunction, and visual disorder were 34.6 (27.3), 30.9 (27.1), and 25.2 (26.5), respectively. Overall, patients exhibited unease about their condition, with a mean (SD) score for future uncertainty of 59.1 (25.7). CONCLUSION(S): Patients with progressive GBM report worse QoL than those with stable disease or those who respond to treatment. These findings suggest a need for effective and tolerable treatments that can conserve patient QoL.